<p>根據 DCM Advisors LLC 最近向證券交易委員會（SEC）提交的文件，該公司在第四季度將其在 CVS Health Co.（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 15.5%。該基金在季度內額外購買了 10,920 股後，持有該藥房運營商的 81,530 股股票。CVS Health 佔 DCM Advisors LLC 持有資產的 1.6%，使其成為該公司第 21 大持倉。截至其最近向證券交易委員會（SEC）提交的文件，DCM Advisors LLC 在 CVS Health 的持股價值為 3,435,000 美元。</p>
<ul>
<li>MarketBeat 週報 – 05/12 - 05/16</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也調整了對該股票的持倉。Orion Capital Management LLC 在第四季度購買了 CVS Health 的新股份，價值約 54,000 美元。McIlrath &amp; Eck LLC 在第四季度將其在 CVS Health 的持股增加了 32.6%。McIlrath &amp; Eck LLC 現在持有 707 股該藥房運營商的股票，價值 32,000 美元，此前在上個季度又購買了 174 股。Novem Group 在第四季度購買了 CVS Health 的新股份，價值約 562,000 美元。NCM Capital Management LLC 在第四季度將其在 CVS Health 的持股增加了 184.2%。NCM Capital Management LLC 現在持有 11,225 股該藥房運營商的股票，價值 504,000 美元，此前在上個季度又購買了 7,276 股。最後，White Knight Strategic Wealth Advisors LLC 在第四季度將其在 CVS Health 的持股增加了 176.0%。White Knight Strategic Wealth Advisors LLC 現在持有 15,740 股該藥房運營商的股票，價值 707,000 美元，此前在上個季度又購買了 10,038 股。80.66% 的股票由機構投資者持有。</p>
<h2>CVS Health 的內部買賣</h2>
<p>在 CVS Health 的其他消息中，高級副總裁 James David Clark 於 3 月 5 日星期三出售了 7,513 股公司的股票。該股票以 66.35 美元的平均價格出售，總交易額為 498,487.55 美元。出售完成後，該高級副總裁現在持有 8,394 股公司股票，價值 556,941.90 美元。這筆交易代表其持倉減少了 47.23%。該出售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司 1.22% 的股票。</p>
<h2>分析師評級變動</h2>
<ul>
<li>現在是購買諾和諾德股票的好時機嗎？</li>
</ul>
<p>一些分析師最近對該公司發佈了報告。摩根士丹利在 4 月 15 日星期二的研究報告中重申了對 CVS Health 股票的 “增持” 評級。Piper Sandler 在 3 月 21 日星期五將 CVS Health 的目標價格從 72.00 美元上調至 74.00 美元，並給予該股票 “增持” 評級。瑞銀集團在 5 月 2 日星期五的研究報告中將 CVS Health 的目標價格從 67.00 美元上調至 71.00 美元，並給予該股票 “中性” 評級。瑞穗在 4 月 9 日星期三的研究報告中將 CVS Health 的目標價格從 70.00 美元上調至 76.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Wolfe Research 在 2 月 11 日星期二的研究報告中將 CVS Health 的目標價格從 67.00 美元上調至 70.00 美元，並給予該股票 “增持” 評級。三位投資分析師對該股票給予了持有評級，十七位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat，該股票的共識評級為 “適度買入”，共識目標價格為 74.94 美元。</p>
<p><strong>查看我們對 CVS 的最新分析</strong></p>
<h2>CVS Health 股價下跌 2.5%</h2>
<ul>
<li>在業績疲軟和 CVS-諾和諾德合作後，艾利 Lilly 值得購買嗎？</li>
</ul>
<p>紐約證券交易所 CVS 週四開盤價為 62.13 美元。該公司的市值為 785.9 億美元，市盈率為 16.97，市盈增長比率為 0.98，貝塔值為 0.60。該公司的流動比率為 0.81，速動比率為 0.60，債務與股本比率為 0.80。CVS Health Co.的 12 個月低點為 43.56 美元，12 個月高點為 72.51 美元。該股票的 50 日移動平均線為 66.41 美元，200 日移動平均線為 59.34 美元。</p>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 5 月 1 日星期四發佈了季度財報。該藥房運營商報告季度每股收益為 2.25 美元，超出共識預期的 1.62 美元，超出幅度為 0.63 美元。CVS Health 的股本回報率為 9.11%，淨利潤率為 1.24%。該公司在本季度的收入為 945.9 億美元，而共識預期為 930.7 億美元。在去年同期，該公司發佈的每股收益為 1.31 美元。該公司的季度收入較去年同期增長了 7.0%。平均而言，股票研究分析師預計 CVS Health Co.在當前財政年度將發佈 5.89 美元的每股收益。</p>
<h2>CVS Health 宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，該分紅於 5 月 1 日星期四支付。4 月 22 日星期二的登記股東獲得每股 0.665 美元的分紅。這代表着每年 2.66 美元的分紅和 4.28% 的收益率。該分紅的除息日期為 4 月 22 日星期二。CVS Health 的分紅支付比率為 63.48%。</p>
<h2>關於 CVS Health</h2>
<p>（免費報告）</p>
<p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康三個部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 CVS Health</li>
<li>澳大利亞證券交易所（ASX）是什麼</li>
<li>300 億美元的人工智能機會：它會推動 Meta 的下一個激增嗎？</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>微軟可能會在歐盟反壟斷案件接近解決時反彈</li>
<li>專家股票交易心理技巧</li>
<li>英特爾重新聚焦：NEX 出售和鑄造轉型標誌着新時代的開始</li>
</ul>
<p><strong>想知道其他對沖基金持有 CVS 的情況嗎？</strong> 請訪問 HoldingsChannel.com 獲取 CVS Health Co. (NYSE:CVS - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>DCM Advisors LLC 在第四季度將其在 CVS Health Co. (NYSE:CVS) 的持股增加了 15.5%，額外購買了 10,920 股，總持股達到 81,530 股，價值 340 萬美元。其他機構投資者也調整了他們的持股。內部交易方面，副總裁 James David Clark 出售了 7,513 股。分析師對 CVS Health 的一致評級為 “適度買入”，目標價格為 74.94 美元。CVS Health 報告第一季度每股收益為 2.25 美元，超出預期，市值為 785.9 億美元</p>

<p>DCM Advisors LLC grew its stake in CVS Health Co. (NYSE:CVS - Free Report) by 15.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 81,530 shares of the pharmacy operator's stock after acquiring an additional 10,920 shares during the quarter. CVS Health accounts for 1.6% of DCM Advisors LLC's holdings, making the stock its 21st biggest position. DCM Advisors LLC's holdings in CVS Health were worth $3,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根據 DCM Advisors LLC 最近向證券交易委員會（SEC）提交的文件，該公司在第四季度將其在 CVS Health Co.（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 15.5%。該基金在季度內額外購買了 10,920 股後，持有該藥房運營商的 81,530 股股票。CVS Health 佔 DCM Advisors LLC 持有資產的 1.6%，使其成為該公司第 21 大持倉。截至其最近向證券交易委員會（SEC）提交的文件，DCM Advisors LLC 在 CVS Health 的持股價值為 3,435,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 05/12 - 05/16</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Orion Capital Management LLC bought a new stake in CVS Health during the 4th quarter worth approximately $54,000. McIlrath &amp; Eck LLC increased its stake in CVS Health by 32.6% during the 4th quarter. McIlrath &amp; Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares in the last quarter. Novem Group bought a new stake in CVS Health during the 4th quarter worth approximately $562,000. NCM Capital Management LLC increased its stake in CVS Health by 184.2% during the 4th quarter. NCM Capital Management LLC now owns 11,225 shares of the pharmacy operator's stock worth $504,000 after purchasing an additional 7,276 shares in the last quarter. Finally, White Knight Strategic Wealth Advisors LLC increased its stake in CVS Health by 176.0% during the 4th quarter. White Knight Strategic Wealth Advisors LLC now owns 15,740 shares of the pharmacy operator's stock worth $707,000 after purchasing an additional 10,038 shares in the last quarter. 80.66% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也調整了對該股票的持倉。Orion Capital Management LLC 在第四季度購買了 CVS Health 的新股份，價值約 54,000 美元。McIlrath &amp; Eck LLC 在第四季度將其在 CVS Health 的持股增加了 32.6%。McIlrath &amp; Eck LLC 現在持有 707 股該藥房運營商的股票，價值 32,000 美元，此前在上個季度又購買了 174 股。Novem Group 在第四季度購買了 CVS Health 的新股份，價值約 562,000 美元。NCM Capital Management LLC 在第四季度將其在 CVS Health 的持股增加了 184.2%。NCM Capital Management LLC 現在持有 11,225 股該藥房運營商的股票，價值 504,000 美元，此前在上個季度又購買了 7,276 股。最後，White Knight Strategic Wealth Advisors LLC 在第四季度將其在 CVS Health 的持股增加了 176.0%。White Knight Strategic Wealth Advisors LLC 現在持有 15,740 股該藥房運營商的股票，價值 707,000 美元，此前在上個季度又購買了 10,038 股。80.66% 的股票由機構投資者持有。</p>
</div><h2>Insider Buying and Selling at CVS Health</h2>
<div class="lb-trans"><h2>CVS Health 的內部買賣</h2>
</div><p>In other CVS Health news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at $556,941.90. This trade represents a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.22% of the company's stock.</p>
<div class="lb-trans"><p>在 CVS Health 的其他消息中，高級副總裁 James David Clark 於 3 月 5 日星期三出售了 7,513 股公司的股票。該股票以 66.35 美元的平均價格出售，總交易額為 498,487.55 美元。出售完成後，該高級副總裁現在持有 8,394 股公司股票，價值 556,941.90 美元。這筆交易代表其持倉減少了 47.23%。該出售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司 1.22% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是購買諾和諾德股票的好時機嗎？</li>
</ul>
</div><p>A number of analysts recently issued reports on the company. Morgan Stanley reissued an &#34;overweight&#34; rating on shares of CVS Health in a research note on Tuesday, April 15th. Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, March 21st. UBS Group upped their price target on CVS Health from $67.00 to $71.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, May 2nd. Mizuho upped their price target on CVS Health from $70.00 to $76.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, April 9th. Finally, Wolfe Research upped their price target on CVS Health from 67.00 to 70.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $74.94.</p>
<div class="lb-trans"><p>一些分析師最近對該公司發佈了報告。摩根士丹利在 4 月 15 日星期二的研究報告中重申了對 CVS Health 股票的 “增持” 評級。Piper Sandler 在 3 月 21 日星期五將 CVS Health 的目標價格從 72.00 美元上調至 74.00 美元，並給予該股票 “增持” 評級。瑞銀集團在 5 月 2 日星期五的研究報告中將 CVS Health 的目標價格從 67.00 美元上調至 71.00 美元，並給予該股票 “中性” 評級。瑞穗在 4 月 9 日星期三的研究報告中將 CVS Health 的目標價格從 70.00 美元上調至 76.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Wolfe Research 在 2 月 11 日星期二的研究報告中將 CVS Health 的目標價格從 67.00 美元上調至 70.00 美元，並給予該股票 “增持” 評級。三位投資分析師對該股票給予了持有評級，十七位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat，該股票的共識評級為 “適度買入”，共識目標價格為 74.94 美元。</p>
</div><p><strong>View Our Latest Analysis on CVS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 CVS 的最新分析</strong></p>
</div><h2>CVS Health Trading Down 2.5%</h2>
<div class="lb-trans"><h2>CVS Health 股價下跌 2.5%</h2>
</div><ul>
<li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li>
</ul>
<div class="lb-trans"><ul>
<li>在業績疲軟和 CVS-諾和諾德合作後，艾利 Lilly 值得購買嗎？</li>
</ul>
</div><p>NYSE CVS opened at $62.13 on Thursday. The company has a market cap of $78.59 billion, a PE ratio of 16.97, a PEG ratio of 0.98 and a beta of 0.60. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $72.51. The stock has a 50 day moving average of $66.41 and a 200-day moving average of $59.34.</p>
<div class="lb-trans"><p>紐約證券交易所 CVS 週四開盤價為 62.13 美元。該公司的市值為 785.9 億美元，市盈率為 16.97，市盈增長比率為 0.98，貝塔值為 0.60。該公司的流動比率為 0.81，速動比率為 0.60，債務與股本比率為 0.80。CVS Health Co.的 12 個月低點為 43.56 美元，12 個月高點為 72.51 美元。該股票的 50 日移動平均線為 66.41 美元，200 日移動平均線為 59.34 美元。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, equities research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 5 月 1 日星期四發佈了季度財報。該藥房運營商報告季度每股收益為 2.25 美元，超出共識預期的 1.62 美元，超出幅度為 0.63 美元。CVS Health 的股本回報率為 9.11%，淨利潤率為 1.24%。該公司在本季度的收入為 945.9 億美元，而共識預期為 930.7 億美元。在去年同期，該公司發佈的每股收益為 1.31 美元。該公司的季度收入較去年同期增長了 7.0%。平均而言，股票研究分析師預計 CVS Health Co.在當前財政年度將發佈 5.89 美元的每股收益。</p>
</div><h2>CVS Health Announces Dividend</h2>
<div class="lb-trans"><h2>CVS Health 宣佈分紅</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.28%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio is 63.48%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，該分紅於 5 月 1 日星期四支付。4 月 22 日星期二的登記股東獲得每股 0.665 美元的分紅。這代表着每年 2.66 美元的分紅和 4.28% 的收益率。該分紅的除息日期為 4 月 22 日星期二。CVS Health 的分紅支付比率為 63.48%。</p>
</div><h2>About CVS Health</h2>
<div class="lb-trans"><h2>關於 CVS Health</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康三個部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>$30B AI Opportunity: Will It Power Meta’s Next Surge?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Microsoft Could Rally as EU Antitrust Case Nears Resolution</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 CVS Health</li>
<li>澳大利亞證券交易所（ASX）是什麼</li>
<li>300 億美元的人工智能機會：它會推動 Meta 的下一個激增嗎？</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>微軟可能會在歐盟反壟斷案件接近解決時反彈</li>
<li>專家股票交易心理技巧</li>
<li>英特爾重新聚焦：NEX 出售和鑄造轉型標誌着新時代的開始</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對沖基金持有 CVS 的情況嗎？</strong> 請訪問 HoldingsChannel.com 獲取 CVS Health Co. (NYSE:CVS - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

DCM Advisors LLC 購買了 10,920 股西維斯（CVS Health Co.，紐約證券交易所代碼：CVS）的股票